⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALKS News
Alkermes Inc. plc
Avadel Receives Unsolicited Proposal from Lundbeck
globenewswire.com
AVDL
ALKS
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 USA - English USA - English
prnewswire.com
ALKS
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
prnewswire.com
ALKS
Alkermes to Participate in Two Upcoming Investor Conferences
prnewswire.com
ALKS
FORM 8.1(a) & (b) (Opening Position Disclosure)
prnewswire.com
ALKS
Alkermes plc Reports Third Quarter 2025 Financial Results
prnewswire.com
ALKS
ALKS
Alkermes Appoints Joshua Reed as Chief Financial Officer
prnewswire.com
ALKS
ALKS
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
prnewswire.com
ALKS
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
prnewswire.com
ALKS
ALKS
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
prnewswire.com
ALKS
ALKS